0001104659-23-095359.txt : 20230825
0001104659-23-095359.hdr.sgml : 20230825
20230825163030
ACCESSION NUMBER: 0001104659-23-095359
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230823
FILED AS OF DATE: 20230825
DATE AS OF CHANGE: 20230825
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LOSCALZO JOSEPH
CENTRAL INDEX KEY: 0001276128
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37990
FILM NUMBER: 231208761
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LEAP THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001509745
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274412575
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 47 THORNDIKE STREET
STREET 2: SUITE B1-1
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617 252 4343
MAIL ADDRESS:
STREET 1: 47 THORNDIKE STREET
STREET 2: SUITE B1-1
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Dekkun Corp
DATE OF NAME CHANGE: 20110107
4
1
tm2324823-5_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-08-23
0
0001509745
LEAP THERAPEUTICS, INC.
LPTX
0001276128
LOSCALZO JOSEPH
C/O LEAP THERAPEUTICS, INC.
47 THORNDIKE STREET SUITE B1-1
CAMBRIDGE
MA
02141
1
0
0
0
0
Stock Option (Right to Buy)
2.21
2023-08-23
4
A
0
15000
0
A
2033-08-23
Common Stock
15000
15000
D
The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of November 23, 2023, February 23, 2024, May 23, 2024 and August 23, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company.
/s/ Douglas E. Onsi as attorney-in-fact for Joseph Loscalzo
2023-08-25